Format

Send to

Choose Destination
Antimicrob Agents Chemother. 2009 Mar;53(3):1260-3. doi: 10.1128/AAC.01453-08. Epub 2009 Jan 5.

Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.

Author information

1
JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA. douglas-biedenbach@jmilabs.com

Abstract

Dalbavancin, a long-acting lipoglycopeptide, was evaluated against 81,673 isolates of staphylococci, enterococci, and streptococci collected from 33 countries during worldwide resistance surveillance (2002 to 2007). Regardless of susceptibility to oxacillin, comparable potencies for dalbavancin against Staphylococcus aureus and coagulase-negative staphylococci from all countries were noted (MIC(90), 0.06 to 0.12 microg/ml). Vancomycin-susceptible Enterococcus spp. had dalbavancin MIC(90)s comparable to those for staphylococci, whereas vancomycin-resistant strains were more resistant (MIC(50), >4 microg/ml). beta-Hemolytic and viridians group streptococci were very susceptible to dalbavancin (MIC(90), <or=0.03 microg/ml). Overall, dalbavancin was >or=16-fold more active than vancomycin against the monitored gram-positive species.

PMID:
19124664
PMCID:
PMC2650578
DOI:
10.1128/AAC.01453-08
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center